Wild-type p53 epitope naturally processed and presented by an HLA-B haplotype on human breast carcinoma cells

Kyriakos P. Papadopoulos, Charles S. Hesdorffer, Nicole Suciu-Foca, Hanina Hibshoosh, Paul E. Harris

Research output: Contribution to journalArticle

Abstract

To broaden the clinical applicability of peptide-based immunotherapy in breast cancer, there is a need to identify further tumor-associated peptide epitopes that are specific for HLA alleles, in addition to HLA-A2. The HLA- B44 haplotype is one of the most common HLA-B haplotypes, occurring in 10-20% of the population. We performed the structural characterization of HLA class I-bound self-peptides presented by a human breast cancer cell line with a HLA-A68, A32, B40, B44 haplotype, to identify potential tumor-specific antigens. Of 13 sequenced peptides, 1 peptide had the HLA-A68 peptide binding motif and 12 peptides had the HLA-B40, B44 peptide binding motif. One of the latter peptides, FEVRVCACPG, shared 100% homology to residues 270-279 of wild-type P53 protein. Our study, thus, provides direct evidence for the natural processing and presentation of p53 epitope 270-279 by HLA-B40, B44- bearing human breast tumor cells. Epitopes spanning this region of P53 may have potential use for immunotherapy in patients expressing HLA-A2 and -B44 supertypes.

Original languageEnglish (US)
Pages (from-to)2089-2093
Number of pages5
JournalClinical Cancer Research
Volume5
Issue number8
Publication statusPublished - Aug 1999
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Papadopoulos, K. P., Hesdorffer, C. S., Suciu-Foca, N., Hibshoosh, H., & Harris, P. E. (1999). Wild-type p53 epitope naturally processed and presented by an HLA-B haplotype on human breast carcinoma cells. Clinical Cancer Research, 5(8), 2089-2093.